Literature DB >> 3055178

Plasmid-mediated beta-lactamase (TEM-7) involved in resistance to ceftazidime and aztreonam.

L Gutmann1, M D Kitzis, D Billot-Klein, F Goldstein, G Tran Van Nhieu, T Lu, J Carlet, E Collatz, R Williamson.   

Abstract

TEM-7, a novel TEM-type beta-lactamase (pI 5.41) encoded on a plasmid of approximately 85 kilobases, was found in a clinical isolate of Citrobacter freundii. Strains containing this enzyme exhibited decreased susceptibility to ceftazidime (64-fold) and aztreonam (16-fold) but not to other third-generation cephalosporins. Addition of a beta-lactamase inhibitor--clavulanic acid, sulbactam, or YTR 830--restored normal susceptibility to associated compounds such as ampicillin, piperacillin, ceftazidime, and aztreonam. DNA-DNA hybridization of an intragenic probe of TEM-1 occurred with a 19-kilobase EcoRI fragment of the plasmid encoding TEM-7. A TEM-2 derivative, TEM-201, with characteristics similar to those of TEM-7 was selected spontaneously in the presence of ceftazidime in vitro.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3055178     DOI: 10.1093/clinids/10.4.860

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  43 in total

1.  Genetic characterization of resistance to extended-spectrum beta-lactams in Klebsiella oxytoca isolates recovered from patients with septicemia at hospitals in the Stockholm area.

Authors:  S W Wu; K Dornbusch; G Kronvall
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Failure of ceftazidime-amikacin therapy for bacteremia and meningitis due to Klebsiella pneumoniae producing an extended-spectrum beta-lactamase.

Authors:  C E Smith; B S Tillman; A W Howell; R N Longfield; J H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Development of "oligotyping" for characterization and molecular epidemiology of TEM beta-lactamases in members of the family Enterobacteriaceae.

Authors:  C Mabilat; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

4.  OHIO-1 beta-lactamase is part of the SHV-1 family.

Authors:  D M Shlaes; C Currie-McCumber; A Hull; I Behlau; M Kron
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

5.  Epidemiology of extended spectrum beta-lactamases.

Authors:  A Philippon; S Ben Redjeb; G Fournier; A Ben Hassen
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

Review 6.  Classification of beta-lactamases: groups 1, 2a, 2b, and 2b'.

Authors:  K Bush
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

7.  Identification of extended-spectrum, AmpC, and carbapenem- hydrolyzing beta-lactamases in Escherichia coli and Klebsiella pneumoniae by disk tests.

Authors:  George A Jacoby; Kelley E Walsh; Victoria J Walker
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

8.  Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility.

Authors:  L B Rice; S H Willey; G A Papanicolaou; A A Medeiros; G M Eliopoulos; R C Moellering; G A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

9.  Multiplicity of TEM-derived beta-lactamases from Klebsiella pneumoniae strains isolated at the same hospital and relationships between the responsible plasmids.

Authors:  C M Chanal; D L Sirot; A Petit; R Labia; A Morand; J L Sirot; R A Cluzel
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

10.  Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.

Authors:  D J Payne; R Cramp; D J Winstanley; D J Knowles
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.